You must follow the format and specific instruction of the memo. Review all of the case information then create the memo. Everyt

Your Job Description

I suppose we couldn’t have the market cornered forever. A French company, FR Pharmaceuticals (FRP for short), is launching a new drug that will be in direct competition with our latest anti-obesity medication. The drug’s called Armexotrol—really rolls off the tongue, right?—and it’s actually something of a known quantity. Armexotrol is already being sold in the European Union, having been approved by the European Medicines Agency late last year. Now they’re shooting for U.S. FDA approval, and everything suggests they’ll have the green light soon. Anyway, I just wanted to give everyone in the leadership team the heads up. Carson already knows, of course, and I’m sure our Chief Information Officer is thinking “not my problem, Wanda!” but I figured more discussions about Armexotrol might come up in the next leadership meeting, so now everyone knows. We’re working with a French marketing company, Véracité, to do some research on FRP. Hopefully we’ll come up with some good strategies for mitigating the loss of market share from their launch. I’ll keep you posted! Wanda Sellers Executive Vice President, Sales and Marketing G-BioSport

You remember Véracité, that marketing company I talked about last week? They were doing research on FRP’s new drug. Well, they work quickly, I’ll give them that! However, I do have concerns about one particular aspect of their report, and I figured you’re the person to ask. Their report included a memo from one of FRP’s employees. An internal memo, sent from a director-level employee through the company’s email system to a few execs. I honestly can’t think of any way they could have gotten their hands on it other than hacking. They included some replies to the email as well—everything looks legit. Maybe Véracité has a source who’s leaking information? That’s just as bad! But…the contents of the email are a serious bombshell. We could definitely use it to set FRP back in their bid for FDA approval. Read it yourself—I’ve put the memo in a separate email—and let me know what you think. Is the law on our side to go ahead and use this information? Or leak it to the press? Wanda Sellers Executive Vice President, Sales and Marketing G-BioSport

Here’s the memo from the FRP employee, as well as a response. Véracité provided translations from French; I have the originals as well if you need them. -W. —Original Message— From: Annette Girard To: Marc Lambert Subject: CONFIDENTIAL – Missing data? Marc, The data sent to the FDA from the latest round of clinical trials isn’t complete. I don’t know who decided to omit the less favorable results—maybe it was an honest mistake? I’d like to believe that, but I doubt it. In case the data was omitted before you received it, let me fill you in. Armexotrol can be unsafe for a small subset of users. It’s a specific interaction, so we didn’t notice the problem in previous trials. However, the health consequences are serious. Not fatal, but very bad. Bad enough to potentially complicate—or ruin—our chance at FDA approval. The news is bad, but hiding the problem is worse! We need to send a corrected data set to the FDA right away. Annette Girard Director of Clinical Research FR Pharmaceuticals —Original Message— From: Marc Lambert To: Annette Girard Subject: Re: CONFIDENTIAL – Missing data? Annette, Thank you for your diligence. We are aware of the concerns; however, even without these data, the FDA has more than enough information to make their determination. Please do not pursue this matter further. Marc

Wanda has raised quite a few concerns about Véracité’s report and the confidential FRP memos within. Despite those concerns, remember that we have no way of verifying the memo or its source with 100% certainty. I’m scheduling a meeting of the entire leadership team to hear everyone’s opinions on how to proceed. You should get an email from Cary as well, outlining the potential legal risks we might face depending on how we proceed. Read it before the meeting. Come prepared! Carson Nelson Chief Executive Officer G-BioSport

When faced with an ethical dilemma at work, we have resources at our fingertips to help us decide what to do. These resources may include our Employee Handbook, key policies and procedures, and standard operating procedures. We also have to be aware of the federal, state, and local laws that may apply to the situation. Here are the key points you should know:

1. Protecting confidential information our most valuable asset, is the responsibility of every person;

2. You must commit to take seriously your responsibility to protect and not reveal or divulge any information that would be of use to our competitors or harmful to the Company if made public;

3. You must not misuse confidential information and you should never use or disclose confidential information to gain a benefit for you or someone else;

4. Data entrusted to our company by external parties is considered confidential information;

5. If not handled carefully, receiving confidential information from a third party can subject the company to unwanted competitive restrictions or liability;

6. When working with a third party to avoid any liability you should ensure that anyone providing information to the company has signed a Non-Disclosure Agreement;

7. Distribution of confidential information should be restricted only to those who have a legitimate business reason to know the information;

8. External confidential information obtained should not be shared with non-company personnel without approval from the Information Assurance Officer and only after there is verification that they are under a Non-Disclosure Agreement with the Company;

9. Using confidential information obtained by a third party through inappropriate means such as misrepresentation or omission of important facts should never be used.

This should help you as you work through this ethical dilemma. Good luck! Rian